Parabilis Medicines, Inc. (PBLS) Stock Score, Valuation & Financial Research

Parabilis Medicines, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PBLS

Parabilis Medicines, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 28.54. These figures are a research snapshot, not a buy or sell recommendation.

What Parabilis Medicines, Inc. does

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Parabilis Medicines is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutic candidates, specifically stabilized helical peptides known as Helicons, which are designed to modulate historically undruggable protein targets. The company relies on external financing, such as venture capital and public offerings, to fund its ongoing clinical trials and operational expenses.

Products and services

  • The company's primary product candidate is zolucatetide (FOG-001), a first-in-class therapy targeting the Wnt/beta-catenin pathway for the treatment of various cancers, including desmoid tumors.

Brands and product families

  • Helicon — Proprietary platform for stabilized helical peptides. Source
  • zolucatetide (FOG-001) — Lead clinical-stage therapeutic candidate. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Competitors and product-market comparisons

  • Pharmaceutical and Biotechnology Companies — The company competes with various established pharmaceutical and biotechnology companies that are developing therapies for cancer and other diseases using different or similar therapeutic modalities. Source

Business strengths to evaluate

  • Proprietary Helicon peptide platform technology Source
  • Experienced leadership team in drug development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, zolucatetide Source
  • Risks associated with clinical trial development and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PBLS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 28.54
Market capitalization:
3.33B (currency not supplied)
Revenue:
USD 148K
Net income:
USD -170.92M
Free cash flow:
USD -124.02M
Cash:
USD 1.09B
Total debt:
USD 47.51M
EPS:
USD -61.10

What stands out

  • Free cash flow is USD -124.02M, negative for the stored period.
  • The balance sheet shows USD 1.09B of cash versus USD 47.51M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.04B using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PBLS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PBLS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PBLS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PBLS to reach sustainable profitability?
  • What does the current share basis reconciled warning mean for the reliability or interpretation of PBLS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research PBLS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.